• Twist Bioscience Corporation recently reported a profitable third quarter with sales of US$96.06 million and net income of US$20.39 million, announced the launch of a new humanized transgenic mouse model for antibody discovery, and welcomed former Vistaprint CEO Trynka Shineman Blake to its board of directors and audit committee.
• These combined developments highlight the company's push for innovation, operational discipline, and leadership depth as it seeks to expand its market presence in the synthetic biology and biotechnology sectors.
• We'll explore how the shift from net loss to net income this quarter could influence the long-term investment narrative for Twist Bioscience.

We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Twist Bioscience Investment Narrative Recap

To be a shareholder in Twist Bioscience, you need to believe in the company’s ability to turn accelerating revenue growth and innovation into sustained profitability, despite past losses. The recent profitable quarter, strong revenue guidance, and the addition of an experienced board member offer renewed optimism, but do not resolve the core short-term catalyst: proving recurring profitability while mitigating risks related to customer concentration and margin sustainability. The impact of these developments is positive for momentum but does not meaningfully reduce the most significant risk around ongoing unprofitability and potential equity dilution.

The launch of Twist’s new humanized transgenic mouse model for antibody discovery stands out as a relevant announcement amid the profitability milestone. This product directly targets the company’s innovation catalyst, aiming to boost differentiation and expand the addressable market in biopharma, which could support longer-term revenue stability and faster adoption among research customers, even as volatility persists in core sequencing revenue streams. Still, investors should be aware that, despite these promising advancements, high customer concentration means a single lost contract could suddenly impact quarterly results...

Twist Bioscience's outlook anticipates $575.7 million in revenue and $81.3 million in earnings by 2028. Achieving this requires 16.7% annual revenue growth and a $166.5 million increase in earnings from the current level of -$85.2 million.

Uncover how Twist Bioscience's forecasts yield a $43.92 fair value, a 71% upside to its current price.

Exploring Other Perspectives

Three individual fair value estimates from the Simply Wall St Community run from US$35.47 to US$99.11 per share, reflecting a wide range of outlooks on Twist’s future. With recent profitability but persistent risks around recurring margins and dilution, you can compare many contrasting viewpoints to find what aligns with your investment approach.

Explore 3 other fair value estimates on Twist Bioscience - why the stock might be worth just $35.47!

Build Your Own Twist Bioscience Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Twist Bioscience research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.